Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SEATTLE--(BUSINESS WIRE)--Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary vaccine platform that results in a long lasting “active” immune response, announced today results from a first-in-man, Phase I/II clinical trial for its immunotherapy product candidate targeting carcinoembryonic antigen (CEA)-expressing cancers, such as colorectal cancer. The immunotherapy drug, called ETBX-011, induced an immune response in advanced colorectal cancer patients and gave encouraging overall survival results.
Help employers find you! Check out all the jobs and post your resume.
